Form 4: Halozyme Therapeutics SVP, Chief Technical Officer, Michael J. LaBarre, Sells Shares Under 10b5-1 Trading Plan

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, sold shares of common stock between February 25 and February 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. LaBarre, the SVP, Chief Technical Officer of Halozyme Therapeutics, Inc., sold shares of the company's common stock.
• The sales occurred between February 25, 2025, and February 27, 2025.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on September 18, 2024.
• On February 25, 2025, 9,300 shares were sold at a weighted average price of $58.007, and 700 shares were sold at a weighted average price of $58.67.
• On February 26, 2025, 9,400 shares were sold at a weighted average price of $58.091, and 600 shares were sold at a weighted average price of $58.648.
• On February 27, 2025, 1,597 shares were sold at a weighted average price of $58.252, and 100 shares were sold at a price of $58.74.
• Following these transactions, LaBarre directly owns 173,756 shares of Halozyme Therapeutics, Inc.
• The sales were conducted through a broker according to the instructions of the 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of stock sales under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to sell shares under 10b5-1 plans to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates